You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Dasiglucagon hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for dasiglucagon hydrochloride and what is the scope of patent protection?

Dasiglucagon hydrochloride is the generic ingredient in two branded drugs marketed by Zealand Pharma and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dasiglucagon hydrochloride has thirty-three patent family members in twenty-four countries.

Two suppliers are listed for this compound.

Summary for dasiglucagon hydrochloride
International Patents:33
US Patents:2
Tradenames:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Clinical Trials: 20
DailyMed Link:dasiglucagon hydrochloride at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for dasiglucagon hydrochloride
Generic Entry Date for dasiglucagon hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for dasiglucagon hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Inreda Diabetic B.V.Phase 2
Filip Krag KnopPhase 2
Steno Diabetes Center CopenhagenPhase 2

See all dasiglucagon hydrochloride clinical trials

Pharmacology for dasiglucagon hydrochloride
Drug ClassAntihypoglycemic Agent
Mechanism of ActionGlucagon Receptor Agonists
Physiological EffectIncreased Glycogenolysis

US Patents and Regulatory Information for dasiglucagon hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zealand Pharma ZEGALOGUE dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-001 Mar 22, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zealand Pharma ZEGALOGUE dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-001 Mar 22, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zealand Pharma ZEGALOGUE (AUTOINJECTOR) dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-002 Mar 22, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Zealand Pharma ZEGALOGUE (AUTOINJECTOR) dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-002 Mar 22, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.